BioPharma Resources

Investigational drug · Phase 3

Cilta-cel

Also called: JNJ-68284528

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

26

Any phase or sponsor naming "Cilta-cel"

First trial start

2019

Nov 7, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cilta-cel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multiple Myeloma

Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Cilta-cel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 186 on PubMed

Also in development for Multiple Myeloma

  • EtentamigABBV-383, TNB-383BPhase 38 trials

    AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis

  • BMS-986348CC-92480, mezigdomidePhase 37 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • GR1803Velinotamig specified specified days., CLN-803Phase 37 trials

    Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)

  • JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials

    Johnson & Johnson (Janssen) · Multiple Myeloma

  • Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials

    Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma

  • CevostamabRO7187797Phase 34 trials

    Roche (Genentech) · Multiple Myeloma

  • IBI3003Phase 34 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma

  • Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials

    Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.